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Purpose of review: Chronic kidney disease affects approximately 3 million Canadians. Ongoing investment in high
quality kidney research is needed to improve the care of patients with kidney disease. The barriers to translating
such research are discussed in this review.
Sources of information: Personal knowledge, research funding body websites, and published reports.
Findings: In this review, we discuss the meaning of the term translational research and present some of the
programs aimed at ensuring efficient translation of scientific discoveries with a discussion of the barriers to
translation. We highlight some successes and barriers to kidney research translation using recent examples of
research in Canadian nephrology. We present the following examples of kidney research: (1) research aimed at
identifying the causative genes for inherited kidney diseases; (2) recent discoveries in cell-based therapies for kidney
disease; (3) an examination of the impact of acute kidney injury in renal transplant patients; and (4) the development of
a kidney failure risk equation to improve prognosis accuracy.
Limitations: This review focuses on research conducted by the authors.
Implications: The process of research translation is prolonged and challenging and therefore requires resources,
patience, and careful planning. With increased awareness and understanding of the barriers to research translation,
researchers and funding bodies can work together to increase the rate at which important research findings reach
clinical practice and improve the care of patients with kidney disease.
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Objectif de l’étude: La néphropathie chronique touche environ 3 millions de Canadiens. Un investissement
soutenu dans la recherche de haute qualité en néphrologie est nécessaire à l’amélioration des soins aux patients.
Dans cette étude, nous abordons les obstacles à l’application de ces recherches.
Sources d’information: Les connaissances personnelles, les sites Web d’organismes de financement de la
recherche, et les rapports publiés.
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Résultats: Dans cette étude, nous traitons de la signification du terme « recherche translationnelle » et présentons
certains des programmes visant à assurer une circulation efficace des découvertes scientifiques, en abordant les
obstacles à la circulation et à l’application. Nous présentons des réussites de circulation de la recherche en
néphrologie, de même que certains obstacles, en recourant à des exemples récents de recherche canadienne en
néphrologie. Nous citons les exemples suivants de recherche en néphrologie: (1) la recherche visant à déterminer
les gènes responsables des néphropathies héréditaires; (2) les découvertes récentes en matière de thérapies
cellulaires pour les néphropathies; (3) l’examen des conséquences d’une insuffisance rénale aiguë chez les patients
ayant subi une transplantation rénale; et (4) l’élaboration d’une équation concernant le risque d’insuffisance rénale
afin d’améliorer la précision du pronostic.
Limites de l’étude: L’étude se concentre sur les recherches effectuées par les auteurs.
Conséquences: Le processus de circulation et d’application de la recherche est long et ardu, si bien qu’il requiert
des ressources, de la patience et une planification étroite. Grâce à une compréhension et une sensibilisation accrues
des obstacles à la circulation de la recherche, les chercheurs et les organismes de financement peuvent travailler
ensemble afin d’accroître le rythme avec lequel les importantes conclusions de recherches atteignent la pratique
clinique et améliorent les soins aux patients atteints de néphropathies.What was known before
There is a rising awareness of the importance of research
translation in the research community. Funding bodies
are recognizing that increased resources are needed to
improve the success rate of translating research findings
into clinical practice.
What this adds
Through specific examples of Canadian nephrology re-
search, the process of research translation is presented,
with a particular emphasis on the barriers to translation.
Lay summary
What is translational research? Often this term is syn-
onymous with “bench-to-bedside”, meaning to find a
way to transform laboratory research into new medicines
or treatments for patients. Going one step further, trans-
lational research also involves making sure that health
care providers are consistently providing recommended
treatments to patients. This review discusses the mean-
ing of translational research within the context of kidney
research. We also highlight the barriers that prevent the
movement of research findings from the laboratory into
clinical practice. Funding bodies and agencies have given
more resources to translational research and have estab-
lished specific programs to this end. This will hopefully
help overcome the barriers of research translation. Here
we discuss, Canadian research, funded by Canadian tax-
payers and donors and performed in the context of a
Canadian national training program, with an emphasis
on the translational aspects of our work. Included are
looks at a basic science approach to identifying inherited
diseases with kidney involvement, cell-based therapies
for kidney disease, an examination of the factors in-
volved in deciding a treatment plan following acutekidney injury, and consideration of risk-based care for
patients with chronic kidney disease. Where do we go
next? How do we ensure the findings of current kidney
research are extended into clinical practice? The road
ahead looks promising as funding agencies stress a bal-
anced approach for both basic science and clinical re-
search, and a focus on programs directed at translating
research findings.
Introduction
Translational research has become a popular term in the
research community, and may have different meanings
depending on the specific situation. When using the
term translational research, many are referring to the
concept of “bench-to-bedside” where knowledge from
basic science is used to produce new drugs and treatment
options for patients. For others, translational research re-
fers to translating research into clinical practice, also
known as knowledge translation, meaning: “the new treat-
ments and research knowledge actually reach the patients
or populations for whom they are intended and are imple-
mented correctly [1]”.
The Institute of Medicine’s Clinical Research Roundta-
ble originally described the model of translational research
as a two-phase process progressing in the first phase from
basic science to clinical research. They named this first
phase T1. The second phase, also known as T2, was de-
fined as the progression from clinical science to everyday
clinical practice and health decision-making [1,2]. In 2011,
Drolet et al. further expanded on this model of transla-
tional research and developed what they called the
Biomedical Research Translation Continuum, with three
“translational chasms”. The first translational chasm
(known as TI) represents the transition from basic science
research to a proposed human or clinical application.
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the proposed human application to a proven clinical appli-
cation, i.e. evaluation of safety and efficacy using clinical
trials. Finally, translational chasm 3 (T3) is the adoption
into clinical practice or essentially knowledge translation
[3]. The recent recognition of the importance of T3 has
led to a growing area of practice-based research. This re-
search can be used to determine if research findings are
being adopted by clinicians and having an impact on pub-
lic health. If practice-based research demonstrates that cli-
nicians are not changing practice, then there has been a
block at T3, and one must determine why the block is
occurring.
Moving laboratory discoveries into the clinical realm
followed by the ultimate goal of a change in clinical
practice or public policy can prove to be extremely chal-
lenging with many barriers along the way. A study that
reviewed articles published in leading basic science jour-
nals found that approximately 25% of articles that re-
ported promising findings resulted in the publication of
a randomized controlled trial, and less than 10% of the
promising findings were introduced into clinical practice
over a period of 20 years [4]. It can frequently take sev-
eral years to bring discoveries made in the laboratory to
the general public. In fact, studies that examined the
average time from publication of a research finding to
adoption into clinical practice have found that the
process takes on average 17 years, a figure that has not
changed much over the past century [5]. Also, a study
conducted in the United States that assessed health care
delivery and utilization by telephone survey and chart
review found that only 55% of patients receive recom-
mended care [6]. Taken together, these statistics illus-
trate that promising research findings rarely make it into
clinical practice, and when they do, there is a significant
lag time between discovery and implementation.
So why does the translation of research prove to be so
difficult? Sung and colleagues refer to the barriers of trans-
lation as “translational blocks”, which can include financial
constraints, regulatory agency burden, fragmented infra-
structure, or a lack of qualified investigators [2]. If not an-
ticipated and without the appropriate resources in place,
these barriers will all result in a lack of research translation.
Despite the concept of translational research being in-
troduced over 30 years ago [7], the subject has only be-
come a major focus over the past decade. This is
illustrated by a sharp rise in publications on the subject,
with the number of publications increasing from only 5
in 1994 to 110 in 2007 [8]. Along with a large number of
publications in the literature, research funding bodies
and training programs have recognized the need in re-
cent years to make translational research a priority.
The Canadian Institutes of Health Research (CIHR) has
made translating knowledge from the research setting tothe public a key component of its mandate, with funding
and educational programs specifically dedicated to know-
ledge translation [9]. The CIHR defines knowledge trans-
lation as: “a dynamic and iterative process that includes
synthesis, dissemination, exchange and ethically sound
application of knowledge to improve the health of
Canadians, provide more effective health services and
products and strengthen the health care system”. A large
driver of the emphasis on knowledge translation by the
CIHR is the increased focus on research governance and
accountability. The CIHR considers it a priority that tax-
payers’ dollars invested into health research result in some
sort of impact on patients [10].
The National Institutes of Health (NIH) established a
National Center for Advancing Translational Sciences
(NCATS) in 2011. Within the NCATS is the Clinical
and Translational Science Award (CTSA) program,
which supports a national consortium of more than 60
medical research institutions. Funding of NCATS has in-
creased on an annual basis, and the requested budget for
2014 is over $665,000,000 [11]. The European Commis-
sion has also followed suit, allocating most of its 6
billion Euro health research budget for 2007–2013 to
pan-European translational research projects. There are
also a growing number of programs across Europe that
offer training in translational research [12].
A kidney specific, national research program within
Canada known as the Kidney Research Scientist Core
Education and National Training (KRESCENT) program
has also made knowledge translation a top priority [13].
The KRESCENT program was founded in 2004 and is
headed by Dr. Kevin Burns, a nephrologist and basic sci-
entist with the University of Ottawa and Dr. Adeera
Levin, a nephrologist and clinical research scientist with
the University of British Columbia. KRESCENT is a
multi-partner collaboration founded by the Canadian
Society of Nephrology, CIHR and the Kidney Founda-
tion of Canada. The program emphasizes translational
research by funding research fellowships to individuals
from various disciplines. Members of the program range
from dietitians to PhD scientists to nephrologists. The
program meets on a bi-annual basis and members share
their diverse research. The concept of “bench-to- bed-
side” is a focal point of the discussion [14]. Fellows
within the KRESCENT program complete their research
training equipped with the skills for research translation.
This skill set is provided formally by guest speakers at
the bi-annual meetings, assignments and grant writing
seminars; and informally by the program heads and col-
laboration with other fellows in the program.
There is clearly rising awareness and funding for
research translation. We present in this review four ex-
amples of recently published and ongoing Canadian
translational research pertinent to nephrology. The
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ence, clinical application, and public health policy, illus-
trating the breadth of work being done by the Canadian
renal community. More importantly, these examples
demonstrate that translation of research is not just a
unidirectional process, but rather provides opportunities
to move bidirectionally between the bench and the bed-
side to ask and answer important questions relevant to
the kidney. The examples presented also highlight some
of the key barriers to successful research translation.
Genetic disorders with renal involvement and cilia
Investigation of fundamental biological processes has
provided critical insights into our understanding of how
organs behave in health and disease. Specifically, interro-
gation of the phenotypic manifestations of gene muta-
tions has informed our understanding of multiple
diseases. In this regard, the kidney is no exception, as
many genetic disorders have some level of renal involve-
ment [15-17]. Whether these disorders solely affect the
kidneys or multiple tissues within the body with accom-
panying renal dysfunction, often there are high rates of
renal morbidity. Among these genetic disorders are the
cystic kidney diseases polycystic kidney disease (PKD)
and nephronophthisis (NPHP) [17,18]. There are mono-
genic diseases that cause solely PKD or NPHP, but they
can also occur as part of a more broad disorder such as
Bardet-Biedl, Joubert, Senior–Løken, and Orofaciodigital
syndromes where end stage renal disease (ESRD) is quite
common [16-18]. The above listed diseases are among
ciliopathies, where the molecular pathology is rooted in
the cellular organelle, the cilium. Cilia are microtubule-
based organelles that protrude from the surface of the
cell with gated cytoplasm and membrane [17-19]. Pri-
mary (or non-motile) cilia are concentrated in several
signaling pathways and serve as major sensors for the
extracellular environment. In kidneys, primary cilia are
present on tubule epithelial cells and are mechanosen-
sory as well as chemosensory, in that they sense urine
flow and the presence of signaling molecules [20].
Dysfunction in cilia, either from loss or alteration of a
cilia-related gene, can lead to the above diseases, often
resulting in over-proliferation of renal tubule cells and
ultimately, cystogenesis [18,20].
For many ciliopathies, researchers involved in basic
scientific studies will have first characterized the causa-
tive gene. One example, is with IFTA-1 (intraflagellar
transport subcomplex A – 1), studied in the model organ-
ism Caenorhabditis elegans [21]. In C. elegans, the IFTA-1
protein was shown to be a component of the IFT complex,
a strong indication that mutation of the human ortholog
WDR35 would likely result in typical ciliopathy pheno-
types. Subsequently, two studies showed that mutations in
IFTA-1/WDR35 (WD repeat protein 35) were causative inSensenbrenner and short-rib polydactyly syndromes, both
of which include cystic kidneys [18,22,23]. Previous
characterization of a gene in model organisms can assist
in narrowing in on causative mutations, as it did for
IFTA-1/WDR35.
Another type of connection between basic and clinical
science can come in the form of a comprehensive study
of a novel gene. The discovery that TMEM237 (trans-
membrane protein 237 or JBTS14, Joubert syndrome 14)
harbored causative mutations in ciliopathy patients pro-
vides such an example [24]. Common characteristics of
Joubert syndrome include the molar tooth sign, hypo-
tonia, ataxia, hyperpnea, and cystic kidneys [24]. This
extensive study not only included data from the sequen-
cing of Canadian and Austrian patients, there were also
functional studies of the TMEM237 performed in C.
elegans, Danio rerio and cultured mammalian cells. To-
gether, these data provided a broad look into the func-
tion of this gene and the consequences of its loss on
human health. One immediate impact from this discov-
ery for patients and their families is genetic testing for
patients to assist in diagnosis and for family members to
identify disease mutation carriers. Two of the three
equally contributing laboratories are from Canada.
Though the discovery of candidate and novel ciliopa-
thy genes affects a relatively small number of patients
directly, there is the potential for a broader impact. Im-
mediate impacts include: enhanced genetic counseling
for families of a diagnosed proband, faster or more ac-
curate diagnosis through sequencing, and – though con-
troversial – the potential for pre-implantation genetic
screening [18]. Though genetic testing can identify a
particular disease (or identify carriers of disease-causing
mutations), the possibility of negative consequences exists,
such as inability to obtain insurance coverage or potential
negative psychological impact [25]. For example, six la-
boratories currently offer genetic testing for TMEM237/
JBTS14, which is discussed above [26]. Another benefit
derived from the deeper comprehension of the molecular
pathology of each disease is the enriched understanding of
human biological processes that may lead to targeted
therapies.
Though loss or mutation of ciliary components leads
to many disorders, cilia may also play a role in acute kid-
ney injury. It has been shown in transplant patients as
well as in mice that upon kidney injury, cilia become sig-
nificantly shorter [27-31]. After the injury, during the
repair phase, cilia were longer than in controls. The
mechanism for this length control remains elusive and
no role has been found for cilia or cilia-related signaling
in kidney injury or subsequent recovery. Despite this, it
is entirely possible that cilia do play a role in kidney in-
jury and recovery because they function as the environ-
mental sensor of the cell, sensing the surrounding
Molnar et al. Canadian Journal of Kidney Health and Disease 2014, 1:18 Page 5 of 10
http://www.cjkhd.org/content/1/1/18conditions [30]. Changes in cilia length have been ob-
served for many of the monogenic ciliopathies (and/or
the corresponding model organisms) [18,20,32]. Because
ciliopathy genes and kidney injury both result in alter-
ation of cilia length, it is possible that common variants
in these genes may alter ability and/or rate of recovery
from kidney injury as well as potentially aiding in predic-
tion of a patient’s prognosis. Likewise, if the role of cilia
in recovery from kidney injury can be elucidated, there
is the potential that it will aid in the discovery of tar-
geted therapeutics. Therefore, research into monogenic
kidney disorders may not only impact patients with
these diseases, but also has the potential to enhance
treatment of other disorders (Table 1).
While elucidating the role of cilia in kidney disease is
an exciting and fascinating topic, this research is still far
from the end goal of changing clinical practice. This re-
search is still primarily at the basic science level and will
need to overcome the barrier of transitioning to a pro-
posed human or clinical application (T1). Presently, the
primary human or clinical application of this research is
genetic screening or counseling, which has its own bar-
riers to widespread adoption into clinical practice due to
concerns about cost and consequences for the patient,
such as the ability to obtain insurance coverage.
Cell-based therapies for kidney disease
As discussed above, the study of fundamental biologic
processes can provide important insights that ultimately
inform prognostic and/or therapeutic applications of these
discoveries. In most cases, as knowledge is translated to-
wards models that more closely reflect human health andTable 1 Future opportunities for research translation
Topic of research Opportunities for research translation
Discovery and characterization
of novel ciliopathy genes
• Genetic counseling for families.
• Accurate diagnosis of a specific condition
• Although controversial, there is the poten
genetic screening.
• Potential for the development of targeted
(genetic disorders and acute kidney injury
Cell based therapies for
kidney disease
• Potential for a novel therapy for the treat
Design of a randomized controlled trial to
derived factors vs. standard care for the t
Acute kidney injury in the
renal transplant population
• Development of a predictive model that
of graft loss or death following an episod
• Potential to use the developed predictive
risk patients for the study of mechanisms
studies could lead to targeted therapies f
controlled trials.
Risk based care for chronic
kidney disease
• Dialysis access planning pathways that in
• Cost utility analyses of referral and treatm
incorporate the KFRE.
• Evaluation of the KFRE against novel biomdisease, further concept refinement is often required. An
example of this refinement process is illustrated by the
challenges that investigators have faced in translating ex-
citing discoveries made more than 20 years ago suggesting
that cell-based therapies have the potential to attenuate or
even repair chronic organ injury. In the 1980’s and 1990’s,
a number of groups described the presence of bone
marrow-derived cell populations with the ability to regen-
erate and/or repair injured organs [33-35]. Recognizing
the therapeutic potential of these fundamental discoveries,
investigators began testing whether such cells could be
grown in the lab and used as either a preventative or re-
generative treatment for chronic injury of the kidney and
other organs.
As these cells were originally thought to work by re-
placing lost or damaged cells in injured tissues [33,36-40],
initial studies focused on complex and often highly inva-
sive infusion strategies to maximize delivery of cells to the
injured organ, such as direct injections into feeding arter-
ies [37,41,42]. While such studies demonstrated often dra-
matic protective effects of cell infusion, enthusiasm for
such strategies as a clinical treatment was tempered by
the invasive nature of the therapy [43]. Around the same
time, concerns were also being raised regarding the safety
of infusing bone marrow-derived cells, with some studies
suggesting the potential for exacerbation of tissue injury
[44,45], and others even reporting uncontrolled growth of
such cells following infusion [46]. Finally, other reports
suggested that diseases such as diabetes and chronic kid-
ney disease (CKD) could impair the tissue protective activ-
ity of these cells [47-54], rendering an autologous cell
treatment strategy for CKD less attractive.Translational chasm
Moving from basic science to a proposed
human/clinical application (T1)
using genetic sequencing.
tial for pre-implantation
therapies
).
ment of progressive CKD.
test the infusion of EOC
reatment of CKD.
Moving from basic science to a proposed
human application (T1) and now towards
a proven clinical application (T2)
would predict the risk
e of AKI.
Moving a clinical research finding into
clinical practice (T3)
model to identify high
of graft loss. Mechanistic
or testing in randomized
Moving a clinical research finding back
to basic science and towards a proposed
human application (T1)
corporate the KFRE. Moving a clinical research finding into
clinical practice and performing practice
based research (T3)ent pathways that
arkers for CKD progression.
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investigators made a key discovery. In most cases, in-
fused bone marrow-derived cells are not retained in sig-
nificant numbers in the injured organ despite exerting
potent protective effects [55-57]. For example, Dr. Yuen
and colleagues demonstrated that treatment with early
outgrowth cells (EOCs), a type of bone marrow-derived
cell that can be grown in large numbers in the lab, was
able to dramatically reduce progression of experimental
diabetic and non-diabetic CKD. Intriguingly, Dr. Yuen
and his colleagues demonstrated that following infusion,
EOCs homed to organs of the reticuloendothelial sys-
tem, such as the liver, spleen, and bone marrow [55-57].
This finding suggested that infused EOCs might lodge in
these organs, working by secreting soluble factors that
act in an endocrine fashion to protect and repair the in-
jured kidney. Subsequent studies revealed that EOCs
and other bone marrow-derived cells do, in fact, release
soluble factors that can mediate a wide variety of benefi-
cial effects in vitro [55,57-60]. The activity of these sol-
uble factors could be maintained even with extensive
dilution, suggesting that these factors could, in fact,
work via an endocrine mode of action [61].
The potency of these factors also suggested that they
might be used directly as a therapy for kidney disease
without the need for, and associated risks of, cell infu-
sion. In this regard, a recent proof-of-principle study
confirmed that infusion of a cell-free preparation of
EOC-derived factors significantly reduced renal injury
and dysfunction in rats with experimental CKD, mimick-
ing the effects of cell injection [61]. Follow-up studies
have further demonstrated that EOC derived factors
have additive renoprotective effects on top of renin-
angiotensin system blockade [62].
Taken together, this work points to the exciting poten-
tial of cell-based treatment for kidney disease and pro-
vides an example of how the iterative process of
translational research can rapidly refine and advance a
novel treatment from the bench to the bedside. Moving
forward, Dr. Yuen is part of a Canadian group of investi-
gators that is currently planning a clinical trial compar-
ing EOC-derived factors against standard of care therapy
in high risk, proteinuric chronic kidney disease patients
who continue to progress on renin-angiotensin system
blockers. While such a trial would provide important
proof-of-concept data supporting a cell-based treatment
strategy for CKD, the long term goal is to identify the
specific factor(s) responsible for the potent renoprotec-
tive activity of EOC therapy. Importantly, the identifica-
tion of these factors would allow potential enhancement
of renoprotection and would alleviate safety concerns re-
garding the administration of unknown proteins that do
not contribute to renoprotection. These promising pre-
clinical results have formed the basis for a proposedclinical trial of EOC-derived factors in patients with
CKD (Table 1).
Now that this basic science research has overcome the
barrier of finding a proposed human or clinical applica-
tion (T1), the next step is to understand if this translates
into clinical safety and effectiveness with phase 1, 2 and
3 clinical trials (T2).
Acute kidney injury
There are several studies in the general population dem-
onstrating that acute kidney injury (AKI) requiring dialy-
sis is associated with an increased risk of death and
chronic kidney disease [63-66]. There is also increasing
evidence that less severe AKI is associated with an in-
creased risk of poor long-term outcomes [67-71]. How-
ever, the impact of AKI on outcomes in the renal
transplant population is less well characterized. We are
aware of two recently published studies that have exam-
ined this issue. Both studies showed that, similar to the
general population, renal transplant patients who experi-
ence AKI have a heightened risk of poor long-term out-
comes [72,73]. With an association between AKI and
poor outcomes among renal transplant patients now be-
ing demonstrated, how can this discovery be translated
to patients and clinical practice?
Further characterization of the association would first
be needed. It remains unclear if all transplant patients
who develop AKI experience worse outcomes. Poten-
tially certain patient characteristics or characteristics of
the AKI event modify the association, and if so, which
characteristics determine a worse prognosis. We propose
to design a study that would examine the association of
key patient and AKI event characteristics with graft loss
and death. The characteristics examined would be easily
ascertainable from large existing health care databases.
The knowledge gained from this research could be used
to develop a predictive model that could serve as a help-
ful tool for clinicians to identify transplant patients at
high risk for poor long-term outcomes following an epi-
sode of AKI. Identifying high-risk renal transplant pa-
tients at hospital discharge could lead to a practice
change of selected patients being followed more closely.
It is our hope that identifying high risk patients would
lead to improved patient outcomes.
However, there are several potential barriers to this re-
search. The first barrier is to successfully design and
conduct the study. The creation of a robust predictive
model requires a large sample size, and patients with a
kidney transplant are relatively small in number. The
next limitation is that of the database itself. Due to the
follow up time required for the study, and the resources
involved with creating a prospective database across
transplant centres, we will utilize already existing health
care databases. Given that this will be a retrospective
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be included. The variables included in the model are also
very important when considering the clinical application
and uptake into clinical practice. Clinicians will want a
predictive model that is easy to use and incorporates
variables that are readily available. Successful implemen-
tation of the model into clinical practice will also require
a knowledge translation plan.
It is our hope that simply identifying high-risk patients
with the model and following them more closely will im-
prove outcomes; however, this may not be the case. Fol-
lowing our development of the predictive model, an
algorithm or management strategy for high-risk patients
will need to be implemented and applied to clinical
practice. Further research will then be needed to test
whether a change in management of high-risk patients
results in a change in clinical endpoints.
The information gained from this study could poten-
tially be used to move from the bedside back to the
bench. The ability to identify high-risk transplant pa-
tients could facilitate the conduct of basic science stud-
ies examining the mechanism by which AKI leads to
death and graft loss. Mechanistic studies could poten-
tially lead to new therapies for testing in randomized
controlled trials (Table 1).
Risk based care for chronic kidney disease
An estimated 3 million Canadians suffer from CKD and
are at risk for cardiovascular events and progression to
kidney failure [74]. While all patients with CKD are at
increased relative risk of kidney failure and all-cause
mortality when compared to individuals without CKD,
the risk for these adverse outcomes can vary greatly,
even for individuals with the same level of estimated
glomerular filtration rate (eGFR)/kidney function [75-77].
For interventions such as vascular access insertion, apply-
ing the same treatment approaches for patients at high
risk for kidney failure to those at low risk can result in un-
necessary cost and potential harm [78]. Even routine inter-
ventions such as renin-angiotensin aldosterone system
(RAAS) inhibitors may have diminished benefits for pre-
venting CKD progression in patients without albuminuria
and higher risks of acute kidney injury and hyperkalemia
in the same individuals when compared to other antihy-
pertensive agents [79,80]. In order to accurately estimate
the risk of kidney failure requiring dialysis or transplant in
an individual patient, we developed the kidney failure risk
equation (KFRE) in 2011 [77].
The KFRE was developed and validated in 8,931 pa-
tients with CKD Stages 3–5 referred for nephrology care
in the provinces of Ontario and British Columbia. We
developed several equations, but our preferred KFREs (4
variable and 8 variable), were entirely laboratory based,
and predicted the outcome of kidney failure in a 2 to5 year horizon with a high degree of accuracy. These
equations will be published with accompanying risk cal-
culators for use on personal computers, tablets and on
every smartphone platform. Links to download the indi-
vidual applications, and the Microsoft Excel version of
the risk calculator were provided as part of the original
publication, and greatly accelerated the knowledge to ac-
tion cycle for the KFRE [77,81].
Concordantly, the KFRE has been validated externally
by several independent investigators and is used rou-
tinely for the triage of nephrology consultations and
dialysis access planning in advanced CKD clinics in mul-
tiple jurisdictions [82-84] (and unpublished observa-
tions). In particular, the province of Manitoba has
adopted a centralized triage process for incoming neph-
rology consultations, where all consults are risk stratified
by the KFRE, and those with a < 3% risk of kidney failure
in the next 5 years are referred back to primary care,
with instructions to re-refer if kidney function declines.
The adoption of this referral strategy has resulted in a
significant reduction in wait times for nephrology care
(10 months to 2 months), and has thereby increased
patient and provider satisfaction for high risk referrals
(unpublished observations). Similar strategies in other
jurisdictions have resulted in better vascular access plan-
ning and more informed treatment modality discussions
in older patients with CKD [84]. Together, these global
and local knowledge translation strategies have greatly
increased the impact of the KFRE, and represent an ex-
ample of translational research from the epidemiology
bench to the health policy bedside (personal communi-
cation, Daniel Schwarz).
Future directions for knowledge translation of the
KFRE include implementation in dialysis access planning
pathways, cost utility analyses of referral and treatment
pathways that incorporate risk, and evaluation of the
KFRE against novel biomarkers for CKD progression
(Table 1).
The largest barrier for this research to overcome is the
widespread uptake into clinical practice (T3). The suc-
cessful uptake by clinicians will require funding and stra-
tegic planning for knowledge translation. Successful
widespread use of the KFRE will likely require a know-
ledge translation action plan followed by repeated follow
up on the results of the action plan with modifications
as needed. These studies will likely include decision ana-
lyses based on real data, as well as cluster randomized
trials or time series analyses measuring the effects of
knowledge translation.
Conclusions
This review highlights four areas of research in Canadian
nephrology conducted by trainees in the KRESCENT
program. The translational nature of the research
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diverse areas of expertise of the researchers highlight the
unique opportunity for collaboration among basic and
clinical scientists afforded by the KRESCENT program.
In this review, important discoveries in the area of neph-
rology and successful examples of research translation
are presented, such as the development of the KFRE in-
fluencing clinical practice and thus improving the care
of renal patients locally in Manitoba. On the other hand,
many barriers to research translation are illustrated in
the research examples presented. For example, the re-
search using cell-based therapies for the treatment of
kidney disease highlights the great many challenges en-
countered and the patience and resources one requires
when looking at successfully translating discoveries made
in the laboratory into a clinical or human application.
It is clear that research translation is often a very diffi-
cult and lengthy process that requires ample resources
and planning. The good news is that funding bodies are
recognizing this and are committed to dedicating re-
sources to the goal of ensuring that scientific discoveries
eventually benefit patients in a timely fashion. Specific
to the area of nephrology, the KRESCENT program has
a mandate to direct its funds towards a balance of clin-
ical and basic science research, providing a comprehen-
sive training program with an emphasis on translational
research and collaboration among investigators enrolled
in the program. With enhanced funding and awareness
over recent years, the success of research translation
should improve over the coming years, ultimately im-
proving the care of patients with kidney disease.Abbreviations
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